Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration

The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration developed an MCDA rating tool to assess and prioritize potential post-market real-world evidence (RWE) questions/uncertainties emerging from public drug funding decisions in Canada. In collaboration with a group of...

Descripción completa

Detalles Bibliográficos
Autores principales: Parmar, Ambica, Dai, Wei Fang, Dionne, Francois, Geirnaert, Marc, Denburg, Avram, Ahuja, Tarry, Beca, Jaclyn, Bouchard, Sylvie, Chambers, Carole, Hunt, Melissa J., Husereau, Don, Lungu, Elena, McDonald, Valerie, Mercer, Rebecca E., Mitera, Gunita, Muñoz, Caroline, Naipaul, Rohini, Peacock, Stuart, Potashnik, Tanya, Tadrous, Mina, Takhar, Pam, Taylor, Marianne, Trudeau, Maureen, Wasney, Danica, Gavura, Scott, Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137247/
https://www.ncbi.nlm.nih.gov/pubmed/37185399
http://dx.doi.org/10.3390/curroncol30040286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137247/
https://www.ncbi.nlm.nih.gov/pubmed/37185399
http://dx.doi.org/10.3390/curroncol30040286

Ejemplares similares